|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kulik L and El-Serag HB: Epidemiology and
management of hepatocellular carcinoma. Gastroenterology.
156:477–491.e1. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Laursen L: A preventable cancer. Nature.
516:S2–S3. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schulze K, Nault JC and Villanueva A:
Genetic profiling of hepatocellular carcinoma using next-generation
sequencing. J Hepatol. 65:1031–1042. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Watson IR, Takahashi K, Futreal PA and
Chin L: Emerging patterns of somatic mutations in cancer. Nat Rev
Genet. 14:703–18. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Llovet JM, Zucman-Rossi J, Pikarsky E,
Sangro B, Schwartz M, Sherman M and Gores G: Hepatocellular
carcinoma. Nat Rev Dis Primers. 2:160182016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Quaas A, Oldopp T, Tharun L, Klingenfeld
C, Krech T, Sauter G and Grob TJ: Frequency of TERT promoter
mutations in primary tumors of the liver. Virchows Arch.
465:673–677. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Totoki Y, Tatsuno K, Covington KR, Ueda H,
Creighton CJ, Kato M, Tsuji S, Donehower LA, Slagle BL, Nakamura H,
et al: Trans-ancestry mutational landscape of hepatocellular
carcinoma genomes. Nat Genet. 46:1267–1273. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nault JC and Zucman-Rossi J: TERT promoter
mutations in primary liver tumors. Clin Res Hepatol Gastroenterol.
40:9–14. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rudolph KL, Hartmann D and Opitz OG:
Telomere dysfunction and DNA damage checkpoints in diseases and
cancer of the gastrointestinal tract. Gastroenterology.
137:754–762. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nault JC, Mallet M, Pilati C, Calderaro J,
Bioulac-Sage P, Laurent C, Laurent A, Cherqui D, Balabaud C and
Zucman- Rossi J: High frequency of telomerase reverse-transcriptase
promoter somatic mutations in hepatocellular carcinoma and
preneoplastic lesions. Nat Commun. 4:22182013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nault JC, Calderaro J, Di Tommaso L,
Balabaud C, Zafrani ES, Bioulac-Sage P, Roncalli M and Zucman-Rossi
J: Telomerase reverse transcriptase promoter mutation is an early
somatic genetic alteration in the transformation of premalignant
nodules in hepatocellular carcinoma on cirrhosis. Hepatology.
60:1983–1992. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee SE, Chang SH, Kim WY, Lim SD, Kim WS,
Hwang TS and Han HS: Frequent somatic TERT promoter mutations and
CTNNB1 mutations in hepatocellular carcinoma. Oncotarget.
7:69267–69275. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pezzuto F, Buonaguro L, Buonaguro FM and
Tornesello ML: Frequency and geographic distribution of TERT
promoter mutations in primary hepatocellular carcinoma. Infect
Agent Cancer. 12:272017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kawai-Kitahata F, Asahina Y, Tanaka S,
Kakinuma S, Murakawa M, Nitta S, Watanabe T, Otani S, Taniguchi M,
Goto F, et al: Comprehensive analyses of mutations and hepatitis B
virus integration in hepatocellular carcinoma with
clinicopathological features. J Gastroenterol. 51:473–486. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zucman-Rossi J, Villanueva A, Nault JC and
Llovet JM: Genetic landscape and biomarkers of hepatocellular
carcinoma. Gastroenterology. 149:1226–1239 e4. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hussain SP, Schwank J, Staib F, Wang XW
and Harris CC: TP53 mutations and hepatocellular carcinoma:
Insights into the etiology and pathogenesis of liver cancer.
Oncogene. 26:2166–2176. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tornesello ML, Buonaguro L, Tatangelo F,
Botti G, Izzo F and Buonaguro FM: Mutations in TP53, CTNNB1 and
PIK3CA genes in hepatocellular carcinoma associated with hepatitis
B and hepatitis C virus infections. Genomics. 102:74–83. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
de La Coste A, Romagnolo B, Billuart P,
Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C,
Kahn A and Perret C: Somatic mutations of the beta-catenin gene are
frequent in mouse and human hepatocellular carcinomas. Proc Natl
Acad Sci USA. 95:8847–8851. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Clevers H and Nusse R: Wnt/β-catenin
signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guichard C, Amaddeo G, Imbeaud S, Ladeiro
Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M,
Degos F, et al: Integrated analysis of somatic mutations and focal
copy-number changes identifies key genes and pathways in
hepatocellular carcinoma. Nat Genet. 44:694–698. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Saitta C, Lanza M, Bertuccio A, Lazzara S,
Navarra G, Raimondo G and Pollicino T: Evaluation of CTNNB1 and
TP53 variability in patients with hepatocellular carcinoma and
occult hepatitis B virus infection. Cancer Genet. 208:513–516.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Statistics INIo. http://dati.istat.it/?lang=en2018
|
|
24
|
Fusco M, Girardi E, Piselli P, Palombino
R, Polesel J, Maione C, Scognamiglio P, Pisanti FA, Solmone M, Di
Cicco P, et al: Epidemiology of viral hepatitis infections in an
area of southern Italy with high incidence rates of liver cancer.
Eur J Cancer. 44:847–853. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dal Maso L, Lise M, Zambon P, Crocetti E,
Serraino D, Ricceri F, Vercelli M, De Lisi V, Tagliabue G, Federico
M, et al: Incidence of primary liver cancer in Italy between 1988
and 2002: An age-period-cohort analysis. Eur J Cancer. 44:285–292.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chalasani N, Younossi Z, Lavine JE,
Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM and Sanyal AJ:
The diagnosis and management of nonalcoholic fatty liver disease:
Practice guidance from the American association for the study of
liver diseases. Hepatology. 67:328–357. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mostaid MS, Ahmed MU, Islam MS, Bin Sayeed
MS and Hasnat A: Lung cancer risk in relation to TP53 codon 47 and
codon 72 polymorphism in Bangladeshi population. Tumour Biol.
35:10309–10317. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu B, Guo D and Guo Y: Association between
p53 Arg72Pro polymorphism and thyroid cancer risk: A meta-analysis.
Tumour Biol. 35:561–565. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang YC, Chen CY, Chen SK, Chang YY and
Lin P: p53 codon 72 polymorphism in Taiwanese lung cancer patients:
Association with lung cancer susceptibility and prognosis. Clin
Cancer Res. 5:129–134. 1999.PubMed/NCBI
|
|
31
|
Jia S, Tang W and Luo Y: p53 codon 72
polymorphism and hepatocellular carcinoma: A meta-analysis. Hepatol
Int. 7:669–675. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zeng XT, Luo W, Geng PL, Guo Y, Niu YM and
Leng WD: Association between the TP53 codon 72 polymorphism and
risk of oral squamous cell carcinoma in Asians: A meta-analysis.
BMC Cancer. 14:4692014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vinagre J, Almeida A, Populo H, Batista R,
Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, et al:
Frequency of TERT promoter mutations in human cancers. Nat Commun.
4:21852013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin
L and Garraway LA: Highly recurrent TERT promoter mutations in
human melanoma. Science. 339:957–959. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Horn S, Figl A, Rachakonda PS, Fischer C,
Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, et al:
TERT promoter mutations in familial and sporadic melanoma. Science.
339:959–961. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda
C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL,
Giovanella BC, et al: TERT promoter mutations occur frequently in
gliomas and a subset of tumors derived from cells with low rates of
self-renewal. Proc Natl Acad Sci USA. 110:6021–6026. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Giedl J, Rogler A, Wild A, Riener MO,
Filbeck T, Burger M, Rummele P, Hurst C, Knowles M, Hartmann A, et
al: TERT core promotor mutations in early-onset bladder cancer. J
Cancer. 7:915–920. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Park CK, Lee SH, Kim JY, Kim JE, Kim TM,
Lee ST, Choi SH, Park SH and Kim IH: Expression level of hTERT is
regulated by somatic mutation and common single nucleotide
polymorphism at promoter region in glioblastoma. Oncotarget.
5:3399–3407. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ko E, Seo HW, Jung ES, Kim BH and Jung G:
The TERT promoter SNP rs2853669 decreases E2F1 transcription factor
binding and increases mortality and recurrence risks in liver
cancer. Oncotarget. 7:684–699. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Eckert D, Buhl S, Weber S, Jäger R and
Schorle H: The AP-2 family of transcription factors. Genome Biol.
6:2462005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Williams T and Tjian R: Analysis of the
DNA-binding and activation properties of the human transcription
factor AP-2. Genes Dev. 5:670–682. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Huang H, Fujii H, Sankila A, Mahler-Araujo
BM, Matsuda M, Cathomas G and Ohgaki H: Beta-catenin mutations are
frequent in human hepatocellular carcinomas associated with
hepatitis C virus infection. Am J Pathol. 155:1795–1801. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zucman-Rossi J, Benhamouche S, Godard C,
Boyault S, Grimber G, Balabaud C, Cunha AS, Bioulac-Sage P and
Perret C: Differential effects of inactivated Axin1 and activated
beta-catenin mutations in human hepatocellular carcinomas.
Oncogene. 26:774–780. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pezzuto F, Izzo F, Buonaguro L, Annunziata
C, Tatangelo F, Botti G, Buonaguro FM and Tornesello ML: Tumor
specific mutations in TERT promoter and CTNNB1 gene in hepatitis B
and hepatitis C related hepatocellular carcinoma. Oncotarget.
7:54253–54262. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Berthon A, Drelon C, Ragazzon B, Boulkroun
S, Tissier F, Amar L, Samson-Couterie B, Zennaro MC, Plouin PF,
Skah S, et al: WNT/β-catenin signalling is activated in
aldosterone-producing adenomas and controls aldosterone production.
Hum Mol Genet. 23:889–905. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Boulkroun S, Samson-Couterie B, Golib-Dzib
JF, Amar L, Plouin PF, Sibony M, Lefebvre H, Louiset E, Jeunemaitre
X, Meatchi T, et al: Aldosterone-producing adenoma formation in the
adrenal cortex involves expression of stem/progenitor cell markers.
Endocrinology. 152:4753–4763. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yoon YJ, Chang HY, Ahn SH, Kim JK, Park
YK, Kang DR, Park JY, Myoung SM, Kim DY, Chon CY and Han KH: MDM2
and p53 polymorphisms are associated with the development of
hepatocellular carcinoma in patients with chronic hepatitis B virus
infection. Carcinogenesis. 29:1192–1196. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhu ZZ, Cong WM, Liu SF, Xian ZH, Wu WQ,
Wu MC, Gao B, Hou LF and Zhu GS: A p53 polymorphism modifies the
risk of hepatocellular carcinoma among non-carriers but not
carriers of chronic hepatitis B virus infection. Cancer Lett.
229:77–83. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhu ZZ, Cong WM, Liu SF, Dong H, Zhu GS
and Wu MC: Homozygosity for Pro of p53 Arg72Pro as a potential risk
factor for hepatocellular carcinoma in Chinese population. World J
Gastroenterol. 11:289–292. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Rebbani K, Marchio A, Ezzikouri S, Afifi
R, Kandil M, Bahri O, Triki H, El Feydi AE, Dejean A, Benjelloun S
and Pineau P: TP53 R72P polymorphism modulates DNA methylation in
hepatocellular carcinoma. Mol Cancer. 14:742015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kołat D, Kałuzińska Ż, Bednarek AK and
Płuciennik E: The biological characteristics of transcription
factors AP-2α and AP-2γ and their importance in various types of
cancers. Biosci Rep. 39(pii): BSR201819282019. View Article : Google Scholar : PubMed/NCBI
|
